Importantly, NLRP3 activation has been detected in myocardial granulomas, suggesting a key role in pathogenesis and supporting IL-1 blockade as a potential targeted therapy for inflammation-driven myocardial damage [42,43]. Here, NLRP3 is linked to Granuloma.